Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04693637 | Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | PHASE2 | COMPLETED | 26 | — | — | Jan 15, 2021 | Jan 19, 2023 | May 9, 2024 | 16 | United States |
The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV through Week 14
| Arm | Type | Description |
|---|---|---|
| Posoleucel (ALVR105) | EXPERIMENTAL | Administered as 2-4 milliliter infusion |
| Name | Type | Description |
|---|---|---|
| Posoleucel (ALVR105) | BIOLOGICAL | Administered as 2-4 milliliter infusion |
Key Inclusion Criteria * ≥1 year of age at the day of screening visit. * Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening * Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clin...